Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
 
Search Article 
  
Advanced search 
  Users Online: 96890 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  
This article has been cited by
1Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes
André J. Scheen
Clinical Pharmacokinetics.2017;56(7)703
[DOI]
2Curcumin improves diabetes mellitus-associated cerebral infarction by increasing the expression of GLUT1 and GLUT3
Mingyu Xia,Zankai Ye,Yanfeng Shi,Libo Zhou,Yang Hua
Molecular Medicine Reports.2017;56(7)703
[DOI]
3In vitro and in silico inhibition properties of fucoidan against a-amylase and a-D-glucosidase with relevance to type 2 diabetes mellitus
Lakshmana Senthil S.,Chandrasekaran Raghu,Arjun H.A.,Anantharaman P.
Carbohydrate Polymers.2019;209(7)350
[DOI]
4The role of dipeptidylpeptidase-4 inhibitors in management of cardiovascular disease in diabetes; focus on linagliptin
Annayya R. Aroor,Camila Manrique-Acevedo,Vincent G. DeMarco
Cardiovascular Diabetology.2018;17(1)350
[DOI]
5Perfil clínico de los pacientes con diabetes mellitus tipo 2 tratados con inhibidores del cotransportador sodio-glucosa tipo 2 y experiencia clínica real en España
Gabriel Cuatrecasas,Fernando Goñi-Goicoechea
Medicina Clínica.2016;147(1)30
[DOI]
  Feedback 
  Subscribe 

Subscribe this journal
Submit articles
Most popular articles
Joiu us as a reviewer
Email alerts
Recommend this journal